Pyxis Oncology launches public offering of common stock and warrants to fund MICVO Phase 3 development

Pyxis Oncology launched a public offering of common stock, pre-funded warrants and warrants, with proceeds intended to fund Phase 3 development of MICVO. No terms were disclosed.

Detected & updated continuously · Source: Nebula